Cory Kasimov
Analyst
JP Morgan
Analyst
Evercore ISI
Equibles does not estimate personal net worth.
About Cory Kasimov
Cory Kasimov is recorded as Analyst at JP Morgan and Analyst at Evercore ISI. Cory Kasimov has spoken on 4 earnings calls across 4 companies, most recently for Alnylam Pharmaceuticals, Inc. on March 31, 2025. Those appearances were for Alnylam Pharmaceuticals, Inc. (ALNY), Biogen Inc. (BIIB), Vertex Pharmaceuticals Inc (VRTX) and Emergent BioSolutions Inc. (EBS). The companies whose calls Cory Kasimov spoke on are classified in the Healthcare sector.
Cory Kasimov on recent calls
“Apologies for asking another one related to cardio transform. But assuming that does, in fact, read out positively, how do you think about the evolution of pricing as another silencer enters the picture, especially given the Part B versus Part D dynamic?”
“I wanted to follow-up on the Phase 3 lecanemab study and can you comment on the enrolled patient population in terms of adequate representation for underrepresented communities that may address the CMS concerns you spoke to?”
“Now that the Phase II VX-864 study has initiated, are there any key differences between this and the VX-814 study that's ongoing on ClinicalTrials.gov? It looks like VX-864 is 40 patients versus 50 patients for VX-814.”
“Actually I have two product-related questions for you and then one big picture one. On the product-related question first and I apologize if this has been addressed but I jumped on a couple of minutes late.”
Affiliation history
-
JP Morgan
Analyst
Source not stated
Current -
Evercore ISI
Analyst
Source not stated
Current
Company network
Biogen Inc.
BIIB
Drug Manufacturers - General · Healthcare
1 appearance
Latest appearance 2022-02-03
View calls and events
Drug Manufacturers - Specialty & Generic · Healthcare
1 appearance
Latest appearance 2009-11-06
View calls and events